Health Canada has conditionally approved lecanemab, a drug designed to slow the progression of early-stage Alzheimer’s disease, prompting discussions about its efficacy and accessibility in Canada. Lecanemab, an artificially created antibody, is administered through intravenous infusion to target the accumulation of amyloid plaques in the brain, a characteristic feature of Alzheimer’s disease.
Although lecanemab is not a cure and cannot reverse the disease or restore lost memories, it marks a significant milestone as the first disease-modifying Alzheimer’s treatment sanctioned for use in Canada. Existing medications primarily alleviate symptoms rather than alter the course of the disease.
The potential effectiveness of the drug and its implications for Canada’s healthcare systems are now key considerations for individuals with Alzheimer’s, their families, healthcare providers, and policymakers.
Eligibility Criteria
Lecanemab, also known as Leqembi, is approved for treating mild cognitive impairment and early stages of Alzheimer’s disease. Patients seeking this treatment must have verifiable amyloid plaque presence in the brain, as stated by the drug manufacturer.
Additionally, patients need to undergo testing for gene variants linked to adverse effects. This medication is solely accessible to patients with one or no copies of the APOE4 gene variant, as individuals with two copies are at higher risk of brain swelling or bleeding. The availability of genetic testing required for eligibility varies among Canadian provinces and territories.
Effectiveness and Concerns
Dr. Sharon Cohen, the medical director at Toronto Memory Program and a clinical trials investigator for the drug, emphasized the importance of having a disease-slowing medication as an initial step in therapeutic approaches. However, questions persist regarding the noticeable impact of lecanemab, especially considering its cost of $26,000 US in other countries.
Dr. Samir Sinha, a geriatrician and clinician scientist at Sinai Health and the University Health Network in Toronto, highlighted the delay in significant outcomes from taking the drug, which poses challenges for its adoption among eligible patients.
Concerns about the practicality and prescription suitability of lecanemab for the majority of patients were raised by Sinha, suggesting the need for further research to ascertain the medication’s overall benefits.
Treatment Process and Monitoring
To confirm eligibility for lecanemab, individuals must undergo specialized diagnostic procedures such as a lumbar puncture or amyloid PET scan. The drug is administered every two weeks via intravenous infusions, each lasting approximately an hour. Ongoing monitoring through PET scans or MRIs is essential to ensure both safety and efficacy.
According to the Alzheimer’s Society, meeting the demands of this treatment will necessitate substantial investments in human resources, infrastructure, training, and the establishment of new healthcare pathways to deliver these treatments effectively and equitably.
Side-Effects and Coverage
The Canadian Consortium on Neurodegeneration in Aging highlighted potential side-effects observed in clinical trials, including brain swelling or bleeding associated with lecanemab and other antibody treatments. Dr. Howard Chertkow, the scientific director of the consortium, likened lecanemab to a modest advancement rather than a significant breakthrough, emphasizing the need for precise identification of patient subgroups that would benefit most from the medication.
The Alzheimer’s Society urged swift public funding and market availability of lecanemab in Canada to ensure affordability for all eligible patients, emphasizing its cost of approximately $26,000 US annually in other countries. While regulatory approval is a crucial step, it may take up to two years for new medications to receive public coverage, with potential access through private or extended benefits in the interim.